Obsidian Therapeutics, Inc. (OBX) shareholders
OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)
Close on Nov 20, 2026Market cap $741.28MP/E –Yield –
Ownership
Who owns Obsidian Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.70%), Peter Kolchinsky (9.70%) and 1 more | 5,957,103 | 9.70% | 13G (passive) | Aug 3, 2026 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (6.60%), Senai Asefaw, M.D. (6.60%) and 1 more | 4,101,576 | 6.60% | 13G (passive) | Sep 28, 2026 |
| Deep Track Capital, LP Joint filing with David Kroin (5.37%), Deep Track Biotechnology Master Fund, Ltd. (5.06%) | 3,315,605 | 5.37% | 13G (passive) | Aug 4, 2026 |
| Novo Holdings A/S | 3,123,992 | 5.10% | 13G (passive) | Aug 3, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Madan Jagasia | Chief Executive Officer, Director | – | – | Nov 13, 2026 |
| Julie B. Feder | Chief Financial Officer | – | – | Nov 13, 2026 |
| Parameswaran Hari | Chief Medical Officer | – | – | Nov 13, 2026 |
| Mark L. Reisenauer | Director | – | – | Nov 13, 2026 |
| Maria Fardis | Director | – | – | Aug 5, 2026 |
| Peter Barrett | Director | – | – | Aug 5, 2026 |
| Heidi Hagen | Director | – | – | Aug 5, 2026 |
| Robert W. Ross | Director | – | – | Aug 5, 2026 |
| Matthew Norkunas | Director | 30,937 | 0.05% | Aug 5, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.92%
1M shares short
Days to cover
3.9
At 0M shares a day
Change since last report
+9.6%
From 1M shares
Short volume, 20 days
60.3%
Of volume reported to FINRA
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Obsidian Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 925,553 shares on Sep 23, 2026 over the last 90 days.
See a number that looks wrong?